Percorrer por autor "Henriques, Camila"
A mostrar 1 - 10 de 17
Resultados por página
Opções de ordenação
- COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older EuropeansPublication . Laniece Delaunay, Charlotte; Mazagatos, Clara; Martínez-Baz, Iván; Túri, Gergő; Goerlitz, Luise; Domegan, Lisa; Meijer, Adam; Rodrigues, Ana Paula; Sève, Noémie; Ilić, Maja; Latorre-Margalef, Neus; Lazar, Mihaela; Maurel, Marine; Melo, Aryse; Andreu Ivorra, Blanca; Casado, Itziar; Horváth, Judit Krisztina; Buda, Silke; Bennett, Charlene; de Lange, Marit; Guiomar, Raquel; Enouf, Vincent; Mlinarić, Ivan; Samuelsson Hagey, Tove; Dinu, Sorin; Rumayor, Mercedes; Castilla, Jesús; Oroszi, Beatrix; Dürrwald, Ralf; O’Donnell, Joan; Hooiveld, Mariëtte; Gómez, Verónica; Falchi, Alessandra; Kurečić Filipović, Sanja; Dillner, Lena; Popescu, Rodica; Bacci, Sabrina; Kaczmarek, Marlena; Kissling, Esther; Gallardo García, Virtudes; Perez Morilla, Esteban; Pedrosa Corral, Irene; García Vázquez, Miriam; Milagro-Beamonte, Ana; Fernandez Ibañez, Ana; Margolles Martins, Mario; Giménez Duran, Jaume; Sastre Palou, Bartolomé; López Causapé, Carla; Viloria Raymundo, Luis Javier; Vega Alonso, Tomás; Ordax Díez, Ana; Lozano Alonso, Jose Eugenio; Rojo Bello, Silvia; Mendioroz, Jacobo; Basile, Luca; Martínez Mateo, Ana Isabel; Ruiz de Porras, Carlota; Moya Garcés, Alba; Marcos, Mª Ángeles; López Maside, Aurora; Botella Quijal, Francesc; Miralles Espi, Maite; Andreu Salete, Cristina; García Rodríguez, María del Carmen; Linares, Juan Antonio; García Comas, Luis; Barranco, Mª Isabel; Chirlaque, María-Dolores; Moreno Docón, Antonio; Ramos Marín, Violeta; Castrillejo, Daniel; Gómez Anés, Atanasio; Larrauro, Amparo; Pérez-Gimeno, Gloria; Lozano Álvarez, Marcos; Vega, Lorena; Galindo, Silvia; Puma, Tania; Monge, Susana; Pozo, Francisco; Casas, Inmaculada; Sandonis, Virginia; Vázquez-Morón, Sonia; Echeverría, Aitziber; Trobajo-Sanmartín, Camino; García Cenoz, Manuel; Ezpeleta, Guillermo; Ezpeleta, Carmen; Navascués, Ana; Krisztalovics, Katalin; Mucsányiné Juhász, Krisztina; Kristóf, Katalin; Preuss, Ute; Wedde, Marianne; Biere, Barbara; Reiche, Janine; Oh, Djin-Ye; McKenna, Adele; Connell, Jeff; Joyce, Michael; Bagheri, Mariam; Bos, Sanne; van den Brink, Sharon; Dijkstra, Frederika; Eggink, Dirk; van Gageldonk-Lafeber, Rianne; Goderski, Gabriel; Herrebrugh, Chantal; Jenniskens, Liz; Reukers, Daphne; Sluimer, John; Sprong, Tara; Teirlinck, Anne; Veldhijzen, Nienke; van der Burgh, Ruben; Kager, Cathrien; Klinkhamer, Mayra; Knottnerus, Bart; Riethof, Marloes; van den Broek, Ruud; Wortel, Safira; Machado, Ausenda; Kislaya, Irina; Aniceto, Carlos; Gomes, Licínia; Verdasca, Nuno; Henriques, Camila; Dias, Daniela; Lança, Miguel; Blanchon, Thierry; Guerrisi, Caroline; Renard, Aubane; Launay, Titouan; Masse, Shirley; Chazelle, Marie; Ferenčak, Ivana; Kaić, Bernard; Višekruna Vučina, Vesna; Čusek Adamić, Katica; Kosanović Ličina, Mirjana Lana; Lakošeljac, Danijela; Mihin Huskić, Ivana; Nonković, Diana; Carnahan, Annasara; Hansson-Pihlainen, Eva; Arvesen, Elin; Nid, Nora; Hansen, Anna-Lena; Andersson, Emmi; Dillner, Lena; Jidovu, Adrian; Timnea, Olivia Carmen; Pascu, Cătălina; Oprea, Mihaela; Bistriceanu, Iulia; Ivanciuc, Alina; Mihai, Maria Elena; VEBIS Primary Care Vaccine Effectiveness GroupKey Points: - Question: What was the effectiveness of COVID-19 vaccines administered in autumn and winter 2022 to 2023 against symptomatic SARS-CoV-2 infection among people aged 60 years or older in Europe, and how did different exposed or reference groups affect effectiveness? - Findings: In this case-control study of 9308 primary care patients at 11 European sites, within 3 months of vaccination, all COVID-19 vaccine effectiveness (CVE) estimates were 29% to 39% against SARS-CoV-2 viruses and 44% to 52% against the XBB variants. All point estimates decreased by time after vaccination, with no vaccine protection after 6 months. - Meaning: Findings of this study suggest that COVID-19 vaccination campaigns should precede peaks in SARS-CoV-2 incidence and that effectiveness of new vaccines against emerging variants should be continually monitored using seasonal CVE approaches.
- Cross-sectional study on protective antibodies against influenza A virus subtypes and cross-protection against influenza A(H3N2) subclade K, Portugal, August 2025Publication . Guiomar, Raquel; Henriques, Camila; Pereira da Silva, Susana; Gomes, Licínia; Dias, Daniela; Verdasca, Nuno; Portuguese Laboratory Network for the Diagnosis of Influenza and Respiratory Viruses; Nunes, Baltazar; Rodrigues, Ana PaulaThe 2025/26 season was marked by co-circulation of influenza A subtypes, with the first detection of A(H3N2) subclade K in September 2025. In August 2025 in Portugal, 14.8% (95% CI: 12.2-17.8) of 886 persons tested had cross-protective antibodies against this subclade. The overall seroprevalence against circulating A(H1N1)pdm09 strains was 28.1% (95% CI: 24.4-32.0). These data highlight the presence of previous cross-reactive antibodies and the possible advantage of vaccination in the extent of detectable antibodies against influenza viruses.
- Dermatophytosis and terbinafine resistances in PortugalPublication . Henriques, CamilaSuperficial mycoses caused by Trichophyton rubrum are among the most common infections worldwide. In Portugal, it is estimated that 1,510,391 of Portuguese suffer from dermatophytosis, corresponding to an incidence of 14,300 per 1,000,000 inhabitants. In a retrospective analysis carried out from 2014 to 2016, with data collected from various hospital institutions in the North and Center of the country and in the metropolitan area of Lisbon, with the aim of evaluating the etiological agents of superficial mycoses diagnosed at national level, comparing their geographic distribution as well as analyzing the species distribution in relation to the cutaneous area involved, 15 different species of dermatophytes were found, with T. rubrum being the most frequent species (53.6%) and the main etiological agent of dermatophytosis of glabrous skin and feet onychomycosis. Superficial mycoses caused by Trichophyton rubrum are among the most common infections worldwide. T. rubrum infections are difficult to treat and are often associated with recurrences after interruption of the antifungal therapy. Terbinafine is one of the allylamine antifungal agents whose target is squalene epoxidase (SQLE). This agent has been extensively used in the therapy of dermatophyte infections. The emergence of resistance to terbinafine in Trichophyton species (namely T. rubrum) has been described recently. The incidence of patients with tinea pedis or unguium tolerant to terbinafine treatment prompted us to screen the terbinafine resistance of Trichophyton isolates obtained by culture at the Mycology Reference Laboratory of the National Institute of Health Doctor Ricardo Jorge. We aimed to determine the frequency of terbinafine resistance and to identify which mutations were involved and their associated mechanism of resistance. Dermatophytes were identified by culture and MALDI-TOF and/or ITS sequencing. All isolates were grown onto agar supplemented with terbinafine in order to detect potential resistant isolates. Antifungal susceptibility testing was performed following CLSI M38A2 broth microdilution method. Among 102 T. rubrum and 17 of T. interdigitale isolates that were tested, 1 T. rubrum isolate (≈1%) and 3 T. interdigitale isolates (≈18%) showed reduced susceptibility to terbinafine. Overall, three isolates showed high terbinafine resistance (MICs, 4 to ≥ 8mg/L) and one isolate displayed moderate terbinafine resistance (MIC, 1 to 2 mg/L). After antifungal susceptibility testing, we sequenced SQLE gene and only 1 isolate from each species were found to harbor different single point mutations in the SQLE gene , leading to single amino acid substitutions at one position (Phe^397) of the SQLE protein. Taken together, our results prompt the current knowledge about the necessity of antifungal susceptibility testing to select effective strategies for management of clinical cases of dermatophytosis not only in Portugal but worldwide.
- Estudo da imunidade adquirida pela vacinação contra a COVID-19 em profissionais de saúde do INSA: relatório de execuçãoPublication . Guiomar, Raquel; Santos, Ana João; Melo, Aryse; Ramalhete, Sara; Costa, Inês; Henriques, Camila; Matos, Rita; Rodrigues, Ana Paula; Irina, Kislaya; Silva, Anabela Santos; Roque, Carla; Silva, Carla; Aguiar, Joaquim; Dias, Carlos; Machado, Jorge; Graça, Fátima; Graça, António Silva; Machado, AusendaO presente relatório de execução, elaborado pelo Departamento de Epidemiologia, o Departamento de Doenças Infeciosas e os Serviços de Saúde Ocupacional do INSA, apresenta os resultados de implementação dos 12 meses do estudo, desenvolvido para estimar a efetividade da vacina contra a COVID-19 em profissionais de saúde do Instituto Nacional de Saúde Doutor Ricardo Jorge (INSA). Neste relatório é apresentada informação sobre a execução do estudo, incluindo descrição dos participantes e da sua participação nos diferentes momentos e etapas, bem como a informação recolhida através das diferentes fontes de dados. O estudo prospetivo de coorte teve como principal objetivo seguir grupos de profissionais vacinados e não-vacinados durante 12 meses para estimar a efetividade da vacina contra a COVID-19 nos trabalhadores do INSA e analisar a resposta imunológica humoral através da deteção de anticorpos vacinais. O estudo iniciou-se em janeiro de 2021 e terminou a 16 fevereiro 2022.
- Evaluation of terbinafine resistance of Trichophyton rubrum and T. interdigitale in Portugal and characterization of the associated resistance mechanismsPublication . Henriques, Camila; Simões, Helena; Veríssimo, Cristina; Sabino, RaquelObjectives: Superficial mycoses caused by Trichophyton rubrum are among the most common infections worldwide. In Portugal, it is estimated that 1,510,391 of Portuguese suffer from dermatophytosis, corresponding to an incidence of 14,300 per 1,000,000 inhabitants. Superficial mycoses caused by Trichophyton rubrum are among the most common infections worldwide, being difficult to treat and often associated with recurrences after interruption of the antifungal therapy. Terbinafine is one of the allylamine antifungal agents whose target is squalene epoxidase (SQLE). This agent has been extensively used in the therapy of dermatophytes’ infections. The emergence of resistance to terbinafine in Trichophyton species has been recently described and is associated with point mutations in the SQLE gene. The increasing number of patients with Tinea pedis or Tinea unguium resistant to terbinafine treatment prompted us to screen the terbinafine resistance in Trichophyton isolates obtained by culture at the Mycology Reference Laboratory of the National Institute of Health Doctor Ricardo Jorge. We aimed to determine the frequency of terbinafine resistance and associated mechanisms of resistance. Materials & Methods: Dermatophytes collected during 2017–2020 were identified by culture and mass spectrometry (MALDI-TOF-MS) and/or by sequencing the ITS (Internal Transcribed Spacers) region of the rDNA. All isolates were grown onto agar supplemented with terbinafine (0.06 and 0.125 mg/L) in order to detect potential resistant isolates. Antifungal susceptibility testing was performed following CLSI M38A2 broth microdilution method. The squalene epoxidase gene (SQLE) was sequenced and mutations described as conferring resistance to terbinafine were screened. Results: Among 102 T. rubrum and 17 of T. interdigitale isolates that identified and further tested in what concerns to their antifungal susceptibility, 1 T. rubrum isolate (≈1%) and 3 T. interdigitale isolates (≈18%) showed to be resistant to terbinafine by screening agar. According to the microdilution method, 2.44% of the isolates were less susceptible to terbinafine. Overall, three isolates (1 T. rubrum and 2 T. interdigitale) showed high terbinafine resistance (MICs, 4 to ≥ 8 mg/L) and one isolate (T. interdigitale) displayed moderate terbinafine resistance (1 to 2 mg/L). The sequencing of the SQLE gene allowed the detection of the following single point mutations: in one T. rubrum and in one T. interdigitale, at the position 1189 in the ORF of the SQLE gene (corresponding to a substitution of a phenylalanine at the position 397 by an isoleucine or by a leucine, respectively). In the remaining resistant T. interdigitale isolates, no mutations were found in the gene encoding SQLE. Although the most common substitutions that lead to higher resistance to terbinafine are L393F and F397L, the F397I substitution detected in our study suggests to be associated with high terbinafine resistance. Conclusions: This study allowed us to detect, for the first time in Portugal, Trichophyton isolates resistant to terbinafine. It was also possible to estimate, within the studied isolates, a resistance frequency of 2.4%. Taken together, our results prompt the current knowledge about the necessity of antifungal susceptibility testing to select effective strategies for management of clinical cases of dermatophytosis not only in Portugal but worldwide.
- Genetic and Epidemiological Insights Into Respiratory Syncytial Virus Infections: A Comparative Study of Hospitalized Versus Community Cases in Portugal (2021-2023)Publication . Lança, Miguel; Gaio, Vânia; Rodrigues, Ana Paula; Henriques, Camila; Gomes, Licínia; Dias, Daniela; Chasqueira, Maria de Jesus; Guiomar, Raquel; Melo, AryseBackground: Respiratory syncytial virus (RSV) is the leading cause of acute respiratory infection (ARI) in young children, but its genetic diversity requires ongoing surveillance. Methods: From 2021 to 2023, a total of 619 and 94 RSV-positive samples from the National Respiratory Syncytial Virus Surveillance Network (VigiRSV) and the Sentinel Influenza and other respiratory viruses surveillance network (Sentinel ISN), respectively, were analysed. The RSV A and RSV B typing was assessed by a multiplex real-time RT-PCR. Sanger sequencing was performed on a subset of samples (n = 495). Phylogenetic analysis was carried out on partial glycoprotein G sequences. Clinical and epidemiological data were compared through Pearson Chi-Square tests. Results: RSV Subgroup A was more prevalent (53.5%, 85/159) in the 2021/2022 season, whereas in the 2022/2023 season, it was RSV Subgroup B (82.1%, 435/530) in both networks. RSV A strains in VigiRSV clustered mainly to A.D.1 (39.0%, 39/100), whereas in Sentinel ISN, they clustered in A.D.5 (30.0%, 3/10). RSV Type B clustered mainly to B.D.E.1 (96.6%, 372/385) in both networks. All lineages cocirculated during the study period and in both surveillance networks. Regional clusters were identified for both subgroups. Conclusions: This study provides new insights into RSV genetic variability in Portugal, namely, the cocirculation of lineages and intravariability among lineages within both subgroups during the study period and in all Portuguese regions. However, our study is based on partial sequencing of the G gene, and because of this limitation, our results should be considered with great caution.
- Nirsevimab Effectiveness Against RSV-Related Hospitalisations in Children Under 24 Months: A Test-Negative Case-Control Study in Portugal, 2024-2025Publication . Gaio, Vânia; Henriques, Camila; Lança, Miguel; Marques, Rita; Marques, Raquel; Rodrigues, Marta; Almeida, Sofia; Sousa, Beatriz; Freitas, Margarida; Amaral, Diana; Ferreira, Sara; Azevedo, Inês; von Hafe, Madalena; Gonçalves, Rafaela; Viseu, Regina; Bandeira, Teresa; Constant, Carolina; Malato, Madalena; Carvalho, Inês; Rodrigues, Jorge; Farinha, Margarida; Nunes, Teresa; Graça, Teresa; Gomez, Sofia; Soares, Sara; Neves, João Farela; Paixão, Paulo; Piscalho, Inês; Loureiro, Ana; Freitas, Cristina; Alves, José; Soares, Diana; Lopes, Paulo; Machado, Ausenda; Guiomar, Raquel; Rodrigues, Ana Paula; VigiRSV GroupWe assessed Nirsevimab effectiveness (NE) against respiratory syncytial virus (RSV)-related hospitalisation in eligible children (< 2 years) using a test-negative case-control design within the VigiRSV network (weeks 43/2024 to 16/2025). Among 341 participants (median age: 2 months; 91.2% without known chronic condition), 137 (40.2%) tested RSV-positive. Adjusted NE against RSV-related hospitalisation was 78.5% (95%CI: 59.3-89.0). Sensitivity analyses confirmed the robustness of the results. These findings support Nirsevimab's effect in a predominantly healthy infant population and contribute to informing public health decisions for RSV immunisation.
- Prevalence of T. rubrum and T. interdigitale Exhibiting High MICs to Terbinafine in Clinical Samples Analyzed in the Portuguese Mycology Reference LaboratoryPublication . Schirmer, Helena; Henriques, Camila; Simões, Helena; Veríssimo, Cristina; Sabino, RaquelCutaneous fungal infections represent a significant burden worldwide with a high impact on public health. Accurate identification of dermatophyte species causing these infections is vital for an appropriate treatment. Terbinafine is the primary agent against Trichophyton species due to its clinical efficacy; however, cases of elevated minimum inhibitory concentration (MIC) have been reported, raising clinical and epidemiological concerns. Herein, we aimed to detect Trichophyton rubrum and Trichophyton interdigitale isolates collected from clinical samples with terbinafine-high MICs (TRB-hMIC). A total of 168 isolates, recovered from 2017 to 2023, were identified as T. rubrum complex (140/83.4%) or T. interdigitale (28/16.7%) and further screened regarding their terbinafine susceptibility. Four isolates with capacity to grow in terbinafine media were detected by screening, and these and a further sixteen random isolates were submitted to the broth microdilution method. This methodology confirmed the four (2.4%) isolates as TRB-hMIC. One T. rubrum and three T. interdigitale showed a minimum inhibitory concentration (MIC) higher than 1 mg/L. Partial sequencing of the SQLE gene identified point mutations in T. rubrum (Phe397Iso) and in one T. interdigitale (Phe397Leu) isolate. Notably, in the other two T. interdigitale isolates with TRB-hMIC, no point mutations in the SQLE gene were identified. In conclusion, TRB-hMIC isolates (T. rubrum and T. interdigitale) were identified in clinical samples analyzed in Portugal, as antifungal susceptibility testing is a crucial routine for identifying treatment failures and also for epidemiological purposes aiming to monitor the dynamics of terbinafine resistance.
- Programa Nacional de Vigilância da Gripe: relatório da época 2022/2023Publication . Verdasca, Nuno; Melo, Aryse; Henriques, Camila; Gomes, Licínia; Lança, Miguel; Dias, Daniela; Silva, Susana Pereira da; Rodrigues, Ana Paula; Guiomar, Raquel; Direcção-Geral da Saúde (colaboração); Rede Portuguesa de Laboratórios para o Diagnóstico da Gripe e Outros Vírus Respiratórios (colaboração)Relatório anual do Programa Nacional de Vigilância da Gripe (PNVG). A presente publicação descreve a caraterização clínica e laboratorial da atividade gripal na época 2022/2023. O PNVG assegura a vigilância epidemiológica da gripe em Portugal, integrando as componentes de vigilância clínica e laboratorial. A componente clínica possibilita o cálculo de taxas de incidência permitindo descrever a intensidade e evolução da epidemia no tempo. A componente virológica tem por base o diagnóstico laboratorial do vírus da gripe, SARS-CoV-2 e vírus sincicial respiratório (RSV) o que permite detetar e caraterizar os vírus respiratórios em circulação em cada inverno. As atividades do PNVG são desenvolvidas pelo Laboratório Nacional de Referência para o Vírus da Gripe e Outros Vírus Respiratórios do Departamento de Doenças Infeciosas e pelo Departamento de Epidemiologia do Instituto Nacional de Saúde Doutor Ricardo Jorge, em colaboração com a Direção-Geral da Saúde. Da descrição da atividade gripal no inverno de 2022/2023 agora apresentada, destacam-se os seguintes resultados: - Na época 2022/2023 a atividade gripal foi de baixa intensidade, tendo sido verificada a epidemia de gripe mais precoce ocorrida nas últimas épocas; - O vírus da gripe A(H3) foi o predominante durante o período epidémico, tendo sido detetados em cocirculação os vírus da gripe A(H1)pdm09 e do tipo B; - A análise virológica demonstrou que os vírus da gripe circulantes eram na sua maioria semelhantes aos vírus que integraram a vacina de 2022/2023. A análise do genoma viral mostrou alguma diversidade genética nos vírus em circulação; - Os vírus SARS-CoV-2 pertenciam na sua maioria à linhagem BA.5 e XBB; - Foi nas crianças entre os 5 e os 14 anos que se detetou a maior percentagem de casos de gripe (33%), seguidas dos jovens e adultos entre os 15 e os 29 anos (26%); - Observou-se um excesso de mortalidade de cerca de 1959 óbitos, no período coincidente com a epidemia de gripe e de frio extremo; - A taxa de admissão de casos confirmados de gripe em UCI registou o valor máximo nas semanas 47/2022 e 10/2023. O vírus influenza tipo A foi identificado na quase totalidade dos casos. Os resultados obtidos no relatório constituem informação útil para a orientação e planeamento de medidas de prevenção e controlo da gripe, SARS-CoV-2, RSV e de outros vírus respiratórios de forma precisa.
- Programa Nacional de Vigilância da Gripe: relatório da época 2023/2024Publication . Guiomar, Raquel; Verdasca, Nuno; Gomes, Licínia; Henriques, Camila; Dias, Daniela; Lança, Miguel; Rodrigues, Ana Paula; Silva, Susana Pereira da; Direcção-Geral da Saúde (colaboração); Rede Portuguesa de Laboratórios para o Diagnóstico da Gripe e Outros Vírus Respiratórios (colaboração)Relatório anual do Programa Nacional de Vigilância da Gripe e de Outros Vírus Respiratórios (PNVG), que descreve a caraterização clínica e laboratorial da atividade gripal na época 2023/2024. O PNVG assegura a vigilância epidemiológica da gripe em Portugal, integrando as componentes de vigilância clínica e laboratorial. A componente clínica possibilita descrever a intensidade e evolução da epidemia no tempo. A componente virológica tem por base o diagnóstico laboratorial do vírus da gripe, SARS-CoV-2 e vírus sincicial respiratório (RSV) o que permite detetar e caraterizar os vírus respiratórios em circulação em cada inverno. As atividades do PNVG são desenvolvidas pelo Laboratório Nacional de Referência para o Vírus da Gripe e Outros Vírus Respiratórios do Departamento de Doenças Infeciosas e pelo Departamento de Epidemiologia do INSA, em colaboração com a Direção-Geral da Saúde.